Coloplast
Egetis attracts a bid and agrees to sell its priority review voucher, Lytix meets its endpoint in melanoma and Novo raises its outlook – the Nordic Pulse | 2026:45
A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3
Analytics
Consensus Analysis | Coloplast | 2026-09-01
Coloplast rapporterar 7 procents tillväxt
Coloplasts interims-vd lämnar styrelsen
Nyhetssvepet onsdag 4 juni
Nyhetssvepet fredag 9 maj
Roche
Nyhetssvepet tisdag 6 maj
Nanexa
Nyhetssvepet onsdag 16 april
BioArctic
Nyhetssvepet tisdag 4 februari
Sedana Medical
Nyhetssvepet onsdag 22 januari
Arctic Bioscience
Nyhetssvepet torsdag 12 december
Mentice